The Impembra Trial, A Phase Ii Study Comparing Pembrolizumab With Intermittent/Short-Term Dual Mapk Pathway Inhibition Plus Pembrolizumab In Melanoma Patients Harboring The Brafv600 Mutation.

Elisa A. Rozeman,Judith M. Versluis,Karolina Sikorska,Ruben Lacroix,Lindsay G Grijpink-Ongering,Birthe Heeres,Bart A. Van De Wiel,Petros Dimitriadis,Ayşegül Sari,Stijn Heijmink,Pia Kvistborg,Daan van den Broek,Annegien Broeks,Jan Willem de Groot,Sofie Wilgenhof,Marieke Anne Vollebergh,Johannes V. Van Thienen,John B. A. G. Haanen,Christian U. Blank

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 6|浏览2

暂无评分

摘要

10021Background: Continuous combination of MAPK inhibition (MAPKi) and anti-PD-(L)1 has been investigated by several trials to improve outcome of BRAFV600 mutated melanoma patients. A major obstacl...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要